The development and challenges faced in bringing the malaria vaccine to Africa. Learn how delays impacted child mortality and the future of vaccine distribution.
When did the first malaria vaccine receive regulatory approval?
- A) 2010
- B) 2015
- C) 2020
- D) 2024
- Answer: B) 2015
When did the malaria vaccine become part of vaccination programs in Africa?
- A) 2015
- B) 2020
- C) 2022
- D) 2024
- Answer: D) 2024
How many children’s deaths could have been averted if the malaria vaccine had arrived 9 years earlier?
- A) 100,000
- B) 143,000
- C) 200,000
- D) 250,000
- Answer: B) 143,000
Who interviewed over 30 scientists and health officials for this report?
- A) Dr. Joe Cohen
- B) Dr. Chris Elias
- C) Stephanie Nolen
- D) Adar Poonawalla
- Answer: C) Stephanie Nolen
In which year did the first babies and toddlers start receiving the malaria vaccine as part of routine childhood shots in Africa?
- A) 2022
- B) 2023
- C) 2024
- D) 2025
- Answer: C) 2024
Which global health agency partnered with GSK to develop the malaria vaccine?
- A) WHO
- B) PATH
- C) Gavi
- D) UNICEF
- Answer: B) PATH
Who provided over $200 million to test the malaria vaccine?
- A) The U.S. Army
- B) The World Health Organization
- C) The Bill & Melinda Gates Foundation
- D) The European Medicines Agency
- Answer: C) The Bill & Melinda Gates Foundation
What year did the clinical trial results show the malaria vaccine cut severe malaria cases by about a third?
- A) 2012
- B) 2013
- C) 2014
- D) 2015
- Answer: C) 2014
Which organization was responsible for buying vaccines for low- and middle-income countries?
- A) UNICEF
- B) WHO
- C) PATH
- D) Gavi
- Answer: D) Gavi
What did the Bill & Melinda Gates Foundation reorient its malaria division towards?
- A) Developing a new vaccine
- B) Eliminating the disease
- C) Distributing bed nets
- D) Improving diagnostic tools
- Answer: B) Eliminating the disease
Which regulatory agency approved the malaria vaccine in 2015?
- A) The FDA
- B) The European Medicines Agency
- C) The CDC
- D) The WHO
- Answer: B) The European Medicines Agency
Which countries were part of the pilot implementation of the malaria vaccine?
- A) Nigeria, Ghana, Kenya
- B) Kenya, Malawi, Ghana
- C) South Africa, Botswana, Zambia
- D) Uganda, Tanzania, Rwanda
- Answer: B) Kenya, Malawi, Ghana
What was the main reason for the delay in the distribution of the malaria vaccine?
- A) Lack of funding
- B) Safety concerns
- C) Manufacturing issues
- D) Political instability
- Answer: B) Safety concerns
What was the production constraint mentioned by GSK for the malaria vaccine?
- A) Lack of raw materials
- B) Old factory
- C) Insufficient demand
- D) Regulatory hurdles
- Answer: B) Old factory
Which company has GSK licensed the malaria vaccine to for production?
- A) Pfizer
- B) Moderna
- C) Bharat Biotech
- D) AstraZeneca
- Answer: C) Bharat Biotech
Which institution developed a second malaria vaccine that moved through clinical trials?
- A) Harvard University
- B) University of Oxford
- C) Johns Hopkins University
- D) Stanford University
- Answer: B) University of Oxford
Which company funded the Phase 3 clinical trial for the second malaria vaccine?
- A) Pfizer
- B) Johnson & Johnson
- C) Serum Institute of India
- D) Moderna
- Answer: C) Serum Institute of India
How many doses does the Serum Institute say it has the capacity to make per year?
- A) 10 million
- B) 50 million
- C) 75 million
- D) 100 million
- Answer: D) 100 million
What is the estimated number of child deaths that could have been prevented if the GSK vaccine had moved through the system as quickly as the Oxford-Serum shot?
- A) 300,000
- B) 450,000
- C) 590,000
- D) 750,000
- Answer: C) 590,000
Which substance used in the malaria vaccine is also used in GSK’s shingles vaccine, Shingrix?
- A) Adjuvant
- B) Antigen
- C) Preservative
- D) Stabilizer
- Answer: A) Adjuvant